Hepatitis B virus (HBV) infects more than 250 million people worldwide and can lead to chronic liver disease and liver cancer. Current antiviral therapies suppress viral replication but do not eliminate the virus, highlighting the urgent need for new strategies to block HBV entry into liver cells.
This article was originally published on MedicalXpress.com

